Specific transgene expression in HIV-infected cells using protease-cleavable transcription regulator

Journal of Controlled Release

Volumn 141, Issue 1, 2010, Pages 52-61

  Asai, Daisuke ^a,b   Kuramoto, Masanori ^c   Shoji, Yoko ^a,b   Kang, Jeong Hun ^b,c   Kodama, Kota Bae ^b   Kawamura, Kenji ^c   Mori, Takeshi ^c   Miyoshi, Hiroshi ^a   Niidome, Takuro ^b,c   Nakashima, Hideki ^a,b   Katayama, Yoshiki ^b,c  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

Coxsackievirus protease; Gene delivery; Gene therapy; HIV; HIV protease

Indexed keywords

CATIONIC PEPTIDES; CELLULAR SIGNALS; GENE DELIVERY; GENE DELIVERY SYSTEMS; GENE REGULATORS; GENE THERAPY; HIV INFECTION; HIV-1 PROTEASE; HIV-PROTEASE; HIV-TAT; INFECTED CELLS; INTRACELLULAR SIGNALING; NEW CONCEPT; NONVIRAL; POLYPLEXES; TARGET CELLS; THERAPEUTIC GENES; TRANSGENE; TRANSGENE EXPRESSION; VIRUS-INFECTED CELLS;

AMINES; CELLS; GENE TRANSFER; INTERNET; PEPTIDES; POLYMERS; TRANSCRIPTION;

VIRUSES;

CATION; PEPTIDE; POLYMER; PROTEINASE; TRANSACTIVATOR PROTEIN;

ARTICLE; CONTROLLED STUDY; COXSACKIE VIRUS B; DRUG DELIVERY SYSTEM; ENZYME SUBSTRATE; GENE ACTIVATION; GENE CONTROL; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; TRANSCRIPTION REGULATION; TRANSGENE; VIRUS CELL INTERACTION;

CATIONS; DNA; DRUG CARRIERS; GENE PRODUCTS, TAT; GENE THERAPY; GENE TRANSFER TECHNIQUES; HIV INFECTIONS; HIV PROTEASE; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; JURKAT CELLS; LUCIFERASES; PARTICLE SIZE; PEPTIDES; POLYMERS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SUBSTRATE SPECIFICITY; TRANSCRIPTION, GENETIC; TRANSGENES;

EID: 70849106158     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2009.08.025     Document Type: Article

References (56)

1. Brenchley J.M., Price D.A., and Douek D.C. HIV disease: fallout from a mucosal catastrophe?. Nat. Immunol. 7 3 (2006) 235-239
2. Derdeyn C.A., and Silvestri G. Viral and host factors in the pathogenesis of HIV infection. Curr Opin Immunol 17 4 (2005) 366-373
3. Baltimore D. Gene therapy. Intracellular immunization. Nature 335 6189 (1988) 395-396
4. Strayer D.S., Akkina R., Bunnell B.A., Dropulic B., Planelles V., Pomerantz R.J., Rossi J.J., and Zaia J.A. Current status of gene therapy strategies to treat HIV/AIDS. Mol. Ther. 11 6 (2005) 823-842
5. Wolkowicz R., and Nolan G.P. Gene therapy progress and prospects: novel gene therapy approaches for AIDS. Gene. Ther. 12 6 (2005) 467-476
6. von Laer D., Hasselmann S., and Hasselmann K. Gene therapy for HIV infection: what does it need to make it work?. J. Gene. Med. 8 6 (2006) 658-667
7. Mulligan R.C. The basic science of gene therapy. Science 260 5110 (1993) 926-932
8. Luten J., van Nostrum C.F., De Smedt S.C., and Hennink W.E. Biodegradable polymers as non-viral carriers for plasmid DNA delivery. J. Control. Release 126 2 (2008) 97-110
9. Li S., and Huang L. Nonviral gene therapy: promises and challenges. Gene. Ther. 7 1 (2000) 31-34
10. Jabr-Milane L., van Vlerken L., Devalapally H., Shenoy D., Komareddy S., Bhavsar M., and Amiji M. Multi-functional nanocarriers for targeted delivery of drugs and genes. J. Control. Release 130 2 (2008) 121-128
11. Hu W.W., Lang M.W., and Krebsbach P.H. Digoxigenin modification of adenovirus to spatially control gene delivery from chitosan surfaces. J. Control. Release 135 3 (2009) 250-258
12. Chang L.J., and He J. Retroviral vectors for gene therapy of AIDS and cancer. Curr. Opin. Mol. Ther. 3 5 (2001) 468-475
13. Qin X.F., An D.S., Chen I.S., and Baltimore D. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc. Natl. Acad. Sci. U S A 100 1 (2003) 183-188
14. Klimatcheva E., Planelles V., Day S.L., Fulreader F., Renda M.J., and Rosenblatt J. Defective lentiviral vectors are efficiently trafficked by HIV-1 and inhibit its replication. Mol. Ther. 3 6 (2001) 928-939
15. Mautino M.R., and Morgan R.A. Enhanced inhibition of human immunodeficiency virus type 1 replication by novel lentiviral vectors expressing human immunodeficiency virus type 1 envelope antisense RNA. Hum. Gene. Ther. 13 9 (2002) 1027-1037
16. Schroers R., Davis C.M., Wagner H.J., and Chen S.Y. Lentiviral transduction of human T-lymphocytes with a RANTES intrakine inhibits human immunodeficiency virus type 1 infection. Gene. Ther. 9 13 (2002) 889-897
17. Li M.J., Bauer G., Michienzi A., Yee J.K., Lee N.S., Kim J., Li S., Castanotto D., Zaia J., and Rossi J.J. Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs. Mol. Ther. 8 2 (2003) 196-206
18. Puls R., and Minchin R. Gene transfer and expression of a non-viral polycation-based vector in CD4+ cells. Gene. Ther. 6 10 (1999) 1774-1778
19. Miyano-Kurosaki N., Barnor J.S., Takeuchi H., Owada T., Nakashima H., Yamamoto N., Matsuzaki T., Shimada F., and Takaku H. In vitro and in vivo transport and delivery of phosphorothioate oligonucleotides with cationic liposomes. Antivir. Chem. Chemother. 15 2 (2004) 93-100
20. Lavigne C., Yelle J., Sauve G., and Thierry A.G. Lipid-based delivery of combinations of antisense oligodeoxynucleotides for the in vitro inhibition of HIV-1 replication. AAPS PharmSci. 3 1 (2001) E7
21. Weber N., Ortega P., Clemente M.I., Shcharbin D., Bryszewska M., de la Mata F.J., Gomez R., and Munoz-Fernandez M.A. Characterization of carbosilane dendrimers as effective carriers of siRNA to HIV-infected lymphocytes. J. Control. Release 132 1 (2008) 55-64
22. Oishi J., Kawamura K., Kang J.H., Kodama K., Sonoda T., Murata M., Niidome T., and Katayama Y. An intracellular kinase signal-responsive gene carrier for disordered cell-specific gene therapy. J. Control. Release 110 2 (2006) 431-436
23. Kang J.H., Asai D., Kim J.H., Mori T., Toita R., Tomiyama T., Asami Y., Oishi J., Sato Y.T., Niidome T., Jun B., Nakashima H., and Katayama Y. Design of polymeric carriers for cancer-specific gene targeting: utilization of abnormal protein kinase Calpha activation in cancer cells. J. Am. Chem. Soc. 130 45 (2008) 14906-14907
24. Kawamura K., Oishi J., Kang J.H., Kodama K., Sonoda T., Murata M., Niidome T., and Katayama Y. Intracellular signal-responsive gene carrier for cell-specific gene expression. Biomacromolecules. 6 2 (2005) 908-913
25. Kawamura K., Oishi J., Sakakihara S., Niidome T., and Katayama Y. Intracellular signal-responsive artificial gene regulation. J. Drug Target 14 7 (2006) 456-464
26. Asai D., Kodama B.K., Shoji Y., Nakashima H., Kawamura K., Oishi J., Kuramoto M., Niidome T., and Katayama Y. Drug delivery system based on responses to an HIV infectious signal. Med. Chem. 4 (2008) 386-391
27. Nakashima H., Masuda M., Murakami T., Koyanagi Y., Matsumoto A., Fujii N., and Yamamoto N. Anti-human immunodeficiency virus activity of a novel synthetic peptide, T22 ([Tyr-5, 12, Lys-7]polyphemusin II): a possible inhibitor of virus-cell fusion. Antimicrob. Agents. Chemother. 36 6 (1992) 1249-1255
28. Muto S., Miyoshi H., Nishikawa H., and Nakashima H. Novel recognition sequence of coxsackievirus 2A proteinase. Biochem. Biophys. Res. Commun. 348 4 (2006) 1436-1442
29. Izumrudov V.A., Zhiryakova M.V., and Kudaibergenov S.E. Controllable stability of DNA-containing polyelectrolyte complexes in water-salt solutions. Biopolymers. 52 2 (1999) 94-108
30. Parker A.L., Oupicky D., Dash P.R., and Seymour L.W. Methodologies for monitoring nanoparticle formation by self-assembly of DNA with poly(l-lysine). Anal. Biochem. 302 1 (2002) 75-80
31. Kawamura K., Kuramoto M., Mori T., Toita R., Oishi J., Sato Y., Kang J.H., Asai D., Niidome T., and Katayama Y. Molecular mechanism of Caspase-3-induced gene expression of polyplexes formed from polycations grafted with cationic substrate peptides. J. Biomater. Sci. Polym. Ed. 20 (2009) 967-980
32. Klabe R.M., Bacheler L.T., Ala P.J., Erickson-Viitanen S., and Meek J.L. Resistance to HIV protease inhibitors: a comparison of enzyme inhibition and antiviral potency. Biochemistry 37 24 (1998) 8735-8742
33. Vives E. Present and future of cell-penetrating peptide mediated delivery systems: "is the Trojan horse too wild to go only to Troy?". J. Control Release 109 1-3 (2005) 77-85
34. Futaki S. Membrane-permeable arginine-rich peptides and the translocation mechanisms. Adv. Drug. Deliv. Rev. 57 4 (2005) 547-558
35. Joliot A., and Prochiantz A. Transduction peptides: from technology to physiology. Nat. Cell. Biol. 6 3 (2004) 189-196
36. Chauhan A., Tikoo A., Kapur A.K., and Singh M. The taming of the cell penetrating domain of the HIV Tat: myths and realities. J. Control. Release 117 2 (2007) 148-162
37. Yamagata M., Kawano T., Shiba K., Mori T., Katayama Y., and Niidome T. Structural advantage of dendritic poly(L-lysine) for gene delivery into cells. Bioorg. Med. Chem. 15 1 (2007) 526-532
38. Kerekatte V., Keiper B.D., Badorff C., Cai A., Knowlton K.U., and Rhoads R.E. Cleavage of Poly(A)-binding protein by coxsackievirus 2A protease in vitro and in vivo: another mechanism for host protein synthesis shutoff?. J. Virol. 73 1 (1999) 709-717
39. Sommergruber W., Casari G., Fessl F., Seipelt J., and Skern T. The 2A proteinase of human rhinovirus is a zinc containing enzyme. Virology 204 2 (1994) 815-818
40. Carr A. Toxicity of antiretroviral therapy and implications for drug development. Nat. Rev. Drug Discov. 2 8 (2003) 624-634
41. Baldwin C.E., Sanders R.W., and Berkhout B. Inhibiting HIV-1 entry with fusion inhibitors. Curr. Med. Chem. 10 17 (2003) 1633-1642
42. De Clercq E., and Schols D. Inhibition of HIV infection by CXCR4 and CCR5 chemokine receptor antagonists. Antivir. Chem. Chemother. 12 Suppl 1 (2001) 19-31
43. Ruff M.R., Polianova M., Yang Q.E., Leoung G.S., Ruscetti F.W., and Pert C.B. Update on D-ala-peptide T-amide (DAPTA): a viral entry inhibitor that blocks CCR5 chemokine receptors. Curr. HIV Res. 1 1 (2003) 51-67
44. Baraz L., Hutoran M., Blumenzweig I., Katzenellenbogen M., Friedler A., Gilon C., Steinitz M., and Kotler M. Human immunodeficiency virus type 1 Vif binds the viral protease by interaction with its N-terminal region. J. Gen. Virol. 83 Pt 9 (2002) 2225-2230
45. Hutoran M., Britan E., Baraz L., Blumenzweig I., Steinitz M., and Kotler M. Abrogation of Vif function by peptide derived from the N-terminal region of the human immunodeficiency virus type 1 (HIV-1) protease. Virology 330 1 (2004) 261-270
46. Vocero-Akbani A.M., Heyden N.V., Lissy N.A., Ratner L., and Dowdy S.F. Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein. Nat. Med. 5 1 (1999) 29-33
47. Nori A., Jensen K.D., Tijerina M., Kopeckova P., and Kopecek J. Tat-conjugated synthetic macromolecules facilitate cytoplasmic drug delivery to human ovarian carcinoma cells. Bioconjug. Chem. 14 1 (2003) 44-50
48. Torchilin V.P., Levchenko T.S., Rammohan R., Volodina N., Papahadjopoulos-Sternberg B., and D'Souza G.G. Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome-DNA complexes. Proc. Natl. Acad. Sci. U S A 100 4 (2003) 1972-1977
49. Gratton J.P., Yu J., Griffith J.W., Babbitt R.W., Scotland R.S., Hickey R., Giordano F.J., and Sessa W.C. Cell-permeable peptides improve cellular uptake and therapeutic gene delivery of replication-deficient viruses in cells and in vivo. Nat. Med. 9 3 (2003) 357-362
50. Rudolph C., Plank C., Lausier J., Schillinger U., Muller R.H., and Rosenecker J. Oligomers of the arginine-rich motif of the HIV-1 TAT protein are capable of transferring plasmid DNA into cells. J. Biol. Chem. 278 13 (2003) 11411-11418
51. Astriab-Fisher A., Sergueev D.S., Fisher M., Shaw B.R., and Juliano R.L. Antisense inhibition of P-glycoprotein expression using peptide-oligonucleotide conjugates. Biochem. Pharmacol. 60 1 (2000) 83-90
52. Koppelhus U., Awasthi S.K., Zachar V., Holst H.U., Ebbesen P., and Nielsen P.E. Cell-dependent differential cellular uptake of PNA, peptides, and PNA-peptide conjugates. Antisense Nucleic Acid Drug Dev. 12 2 (2002) 51-63
53. Bhorade R., Weissleder R., Nakakoshi T., Moore A., and Tung C.H. Macrocyclic chelators with paramagnetic cations are internalized into mammalian cells via a HIV-tat derived membrane translocation peptide. Bioconjug. Chem. 11 3 (2000) 301-305
54. Moulton H.M., Hase M.C., Smith K.M., and Iversen P.L. HIV Tat peptide enhances cellular delivery of antisense morpholino oligomers. Antisense Nucleic Acid Drug Dev. 13 1 (2003) 31-43
55. Geleziunas R., Bour S., and Wainberg M.A. Cell surface down-modulation of CD4 after infection by HIV-1. FASEB J. 8 9 (1994) 593-600
56. Asai D., Tsuchiya A., Kang J.H., Kawamura K., Oishi J., Mori T., Niidome T., Shoji Y., Nakashima H., and Katayama Y. Inflammatory cell-specific transgene expression system responding to Ik-B kinase beta activation. J. Gene Med. 11 7 (2009) 624-632